source
- Iambic Therapeutics CEO discusses $150 million IPO and AI's evolving role in drug developmentIambic Therapeutics completed a $150 million initial public offering, raising fresh capital and seeing its share price climb to about $24.50, roughly a 50% increase from earlier in the week. CEO T…
- Novartis ends mid-stage Fabhalta trial in lupus nephritis citing strategic considerationsNovartis has terminated its mid-stage trial of Fabhalta (iptacopan) in patients with lupus nephritis, according to a federal clinical trials registry. The company said the decision was driven by s…